Skip to main content
Bodil Als-Nielsen on Muck Rack

Bodil Als-Nielsen

As seen in: Nature, Physician's Weekly
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bodil

Contact Bodil, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study - Leukemia

|
By Bodil Als-Nielsen, Birgitte Klug Albertsen, Andreja Dimitrijevic, Henrik Hjalgrim, Marianne Ifversen, Line Stensig Lynggaard, Marianne Olsen, Ulrik Malthe Overgaard, Cecilie Utke Rank, Mathias Rathe, Klaus Rostgaard, Kjeld Schmiegelow, Liv Andrés-Jensen, Camilla Grud Nielsen, Ólafur Birgir Davídsson, Louise Lundgren
| Nature Verified
Abstract With increasing survival in acute lymphoblastic leukemia (ALL), long-term toxicities have become a critical aspect. A novel measure, designated Severe Toxicity-free survival (STFS), was developed through international consensus to integrate the most severe, symptomatic organ toxicities in outcome evaluation. This measure has not been applied to real-world data before.
Open in Who Shared Issue with article?

PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.

|
By Line Stensig Lynggaard, Cecilie U Rank, Bodil Als-Nielsen, Sofie G Hoejfeldt
| Physician's Weekly
Asparaginase has played a crucial role in the improvement of survival in children with acute lymphoblastic leukaemia (ALL), which is the commonest cancer among children. Survival rates have steadily increased over decades since the introduction of asparaginase to ALL therapy, and overall survival rates reach 90% with the best contemporary protocols.
Open in Who Shared Issue with article?
See all 2 articles